 | |
| Clinical data | |
|---|---|
| Other names | LSD-Azepane; Lysergic acid azepane; Lysergic acid hexamethylene imide;N-(Azepan-1-yl)lysergamide |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H27N3O |
| Molar mass | 349.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LA-Azepane, orLSD-Azepane, also known aslysergic acid azepane or aslysergic acid hexamethylene imide, is achemical compound of thelysergamide family related tolysergic acid diethylamide (LSD).[1] It is anderivative of LSD in which theN,N-diethylamidemoiety has beencyclized to form anazepanering.[1] The compound is very little studied and described itself, but is closely related to other amide-cyclized LSDanalogues includingLA-Pip,LSM-775 (LA-Morph),LPD-824 (LA-Pyr),LPN,LSZ (LA-Azetidide), andLA-Aziridine, among others.[2][3] Thechemical synthesis of the compound has been described.[1] LA-Azepane was first described in the literature in apatent by Richard P. Pioch atEli Lilly and Company in 1961.[1] The patent had been filed 5 years previously in 1956.[1]
Table 1 5-HT2A 5-HT2C, and 5-HT1A receptor affinity and functional effects for selected lysergamides [...]
 | Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |